A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Public ClinicalTrials.gov record NCT02659020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Study identification
- NCT ID
- NCT02659020
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 310 participants
Conditions and interventions
Conditions
Interventions
- Olaratumab Drug
- Gemcitabine Drug
- Docetaxel Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2016
- Primary completion
- Jul 27, 2020
- Completion
- Apr 26, 2021
- Last update posted
- May 8, 2022
2016 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center | Santa Monica | California | 90404 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Mayo Clinic-Jacksonville | Jacksonville | Florida | 32224 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Georgia Cancer Specialists PC | Atlanta | Georgia | 30342 | — |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21287 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University Medical School | St Louis | Missouri | 63110 | — |
| Nebraska Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
| Monter Cancer Center | Lake Success | New York | 11042 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| Oklahoma Cancer Specialists & Research Institute, LLC | Tulsa | Oklahoma | 74146 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-6307 | — |
| University of Texas Southwestern Medical Center at Dallas | Dallas | Texas | 75390 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02659020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02659020 live on ClinicalTrials.gov.